<div id="readability-page-1"><p>William Blair analyst Andy Hsieh has maintained their bullish  stance on <span>EXEL</span> stock, giving a Buy rating on April 21.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Andy Hsieh has given his Buy rating due to a combination of factors tied to Exelixis’s commercial strength and clinical momentum. He believes the slower-than-anticipated event rate in the Phase III STELLAR-304 trial of zanzalintinib plus Opdivo in non-clear cell renal cell carcinoma is an encouraging signal, especially given supportive prior data from PAPMET and Merck’s KEYNOTE-B61 that validate this therapeutic approach.</p> <p>He also highlights the durability of the Cabometyx franchise, which continues to generate substantial revenue despite temporary headwinds from inventory dynamics and higher gross-to-net adjustments. After normalizing for these seasonal effects, he views underlying demand as solid, and he sees incremental shareholder value from Exelixis’s substantial ongoing share repurchase program, including a new $750 million authorization through 2027.</p> <p>In another report released on April 21, Goldman Sachs also maintained a Buy rating on the stock with a $50.00 price target.</p></div>

EXEL

SBIO

<p>William Blair analyst Andy Hsieh has reiterated a Buy rating on Exelixis (EXEL) due to strong commercial performance and clinical momentum, particularly from the STELLAR-304 trial. He notes the encouraging event rate in the trial and the durability of the Cabometyx franchise, despite some temporary challenges. Hsieh also emphasizes the value from Exelixis's share repurchase program, which includes a new $750 million authorization through 2027. Goldman Sachs also maintains a Buy rating with a $50 price target.</p>

Tip Ranks

Exelixis

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares Biotechnology ETF

SPDR S&P Biotech

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

VG Health

Ark Genomic Revolution ETF

VanEck Biotech ETF

Merck

Goldman Sachs

GS Hldg R

Analyst Reiterates Buy on Exelixis, Citing STELLAR-304 Momentum, Cabometyx Durability, and Share Repurchases